B+
Bull case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-04-19 · RankAlpha Sentiment Codex
AVBP
ArriVent BioPharmaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive case is that firmonertinib has completed enrollment in the pivotal FURVENT trial with topline data due in mid-2026, ALPACCA has begun dosing in PACC-mutant NSCLC, and the company reported $312.8 million of cash and investments with expected runway into 3Q 2027, limiting near-term financing pressure while multiple oncology shots mature. [#10-K-2026-03-05] [#IR-2026-03-05]
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.3.
What can break
FURVENT topline efficacy or safety disappointment would directly impair the core thesis.
Momentum
28
Value
41
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.00 · Bull $42.00 · Bear $19.00Analysis 2026-04-19; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $44.91
Why
Momentum28 · Δ7d -17.9
Value41 · Δ7d -0.0
Sentiment62 · Δ7d +5.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.3.
Contradictions & invalidation
- • FURVENT topline efficacy or safety disappointment would directly impair the core thesis.
- • Future capital needs remain likely beyond the current runway, especially if development expands or timelines slip. [#10-K-2026-03-05]
- • The bearish case is that AVBP remains predominantly a clinical-outcome story centered on firmonertinib, with low catalyst density before the mid-2026 readout and only early-stage ADC programs as partial diversification.
Catalyst clock
2026-04-21
AACR 2026 preclinical posters for firmonertinib and ARR-002
Lead driver: Sentiment · See AI snapshot
Momentum
28
9% active weight
Current posture
7d trendSoftening
Δ7d
-17.9
Δ21d
-2.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
62
62% active weight
Current posture
7d trendImproving
Δ7d
+5.3
Δ21d
+0.2
Why this grade
Composite grade C. Momentum 27.6 / Value 41.2 / Sentiment 62.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-19. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-04-19 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-04-19 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.43B
Beta
-
Shares Out
49.31M
P/E (TTM) · Derived
-6.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.69
Rev YoY
-
EPS YoY
+16.8%
Gross Margin
-
Op Margin
-
Net Debt
-$312.81M
Current Ratio
14.16
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data